TransMedics Group, Inc. (NASDAQ:TMDX) Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 657.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 64,400 shares of the company’s stock after purchasing an additional 55,900 shares during the quarter. Handelsbanken Fonder AB owned 0.19% of TransMedics Group worth $10,111,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Wasatch Advisors LP purchased a new position in TransMedics Group in the 1st quarter valued at approximately $32,162,000. Vaughan Nelson Investment Management L.P. purchased a new position in TransMedics Group in the second quarter valued at $39,862,000. Driehaus Capital Management LLC grew its stake in TransMedics Group by 15.8% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after purchasing an additional 202,867 shares in the last quarter. First Light Asset Management LLC increased its holdings in TransMedics Group by 22.0% during the 4th quarter. First Light Asset Management LLC now owns 754,317 shares of the company’s stock worth $59,538,000 after purchasing an additional 136,217 shares during the period. Finally, Hood River Capital Management LLC acquired a new stake in TransMedics Group in the 2nd quarter valued at about $18,854,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Morgan Stanley upped their target price on shares of TransMedics Group from $104.00 to $145.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. Needham & Company LLC started coverage on shares of TransMedics Group in a report on Wednesday, August 21st. They set a “buy” rating and a $208.00 price target for the company. Robert W. Baird started coverage on shares of TransMedics Group in a research report on Tuesday, September 24th. They set an “outperform” rating and a $200.00 price objective for the company. Canaccord Genuity Group increased their target price on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, Oppenheimer lifted their price target on TransMedics Group from $125.00 to $200.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $174.30.

Insider Buying and Selling at TransMedics Group

In related news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $3,267,557.11. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $156.77, for a total transaction of $463,725.66. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at $3,267,557.11. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,205 shares of company stock worth $10,089,374. 7.00% of the stock is owned by company insiders.

TransMedics Group Stock Down 3.5 %

Shares of NASDAQ TMDX opened at $134.11 on Tuesday. The stock has a market cap of $4.42 billion, a PE ratio of -394.44 and a beta of 1.99. TransMedics Group, Inc. has a 52-week low of $36.42 and a 52-week high of $177.37. The business has a 50-day moving average price of $156.02 and a 200 day moving average price of $134.55. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company’s revenue was up 117.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) earnings per share. Equities research analysts forecast that TransMedics Group, Inc. will post 1.22 earnings per share for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.